Skip to main content
MindBio Therapeutics Corp. logo

MindBio Therapeutics Corp. — Investor Relations & Filings

Ticker · MBIO ISIN · CA60256C2076 CSE Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 113 across all filing types
Latest filing 2026-01-08 Regulatory Filings
Country CA Canada
Listing CSE MBIO

About MindBio Therapeutics Corp.

https://mindbiotherapeutics.com/

MindBio Therapeutics Corp. develops and commercializes AI-powered health prediction technologies utilizing proprietary acoustic biomarkers extracted from the human voice. The company's core offering is a comprehensive enterprise platform designed for real-time intoxication and impairment detection, primarily focusing on sobriety verification in safety-critical environments. This platform employs machine learning algorithms to analyze over 140 acoustic parameters, such as jitter, shimmer, and spectral entropy, achieving greater than 88% prediction accuracy in under three seconds. Target markets include zero-tolerance industries like aviation, mining, and construction, requiring scalable, non-invasive fitness-for-duty verification. The technology transforms speech into actionable health intelligence for workforce monitoring and advanced telehealth applications.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing that the CEO of MindBio Therapeutics will be presenting at an upcoming industry conference (9th Annual Neuroscience Innovation Forum). It provides details about the company's technology and upcoming investor meetings but does not constitute a formal financial report, proxy statement, or regulatory filing. As it is a general corporate announcement regarding company activities and events, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2026-01-08 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 45-106F1 Report of Exempt Distribution', which is a standard Canadian regulatory filing used to report the distribution of securities under prospectus exemptions. This document details the issuer, the nature of the distribution, the purchasers, and compensation paid to intermediaries. It is a specific regulatory filing required by Canadian securities commissions and does not fit into categories like Annual Reports, Earnings Releases, or Investor Presentations. Therefore, it is classified as a Regulatory Filing (RNS).
2025-12-19 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that MindBio Therapeutics has engaged a third-party firm (Senergy Communications Capital) for marketing and investor awareness services. This type of corporate announcement regarding service provider engagement does not fit into specific financial reporting categories like 10-K, IR, or ER. As it is a general corporate announcement that does not fall into the other specialized categories, it is best classified as a general regulatory filing.
2025-12-15 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a formal notice sent to securities administrators regarding an upcoming Annual General Meeting (AGM). It specifies the meeting date, record dates, and voting eligibility. It is a procedural notification regarding the meeting logistics rather than the proxy materials themselves or the results of the meeting, making it a regulatory filing related to meeting preparation.
2025-12-08 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a corporate press release announcing the issuance of Restricted Stock Units (RSUs) to directors, executives, staff, and suppliers in lieu of cash compensation, and the conversion of payables into new shares. This constitutes a capital change via new share issuance rather than a full financial report or regulatory filing. According to the classification definitions, announcements of new share issues or other capital changes fall under Share Issue/Capital Change (SHA).
2025-10-08 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a corporate press release detailing updates on clinical trials and corporate activity, including convertible loans into subsidiary equity and the board-approved issuance of 61,500,000 Restricted Stock Units under the Company’s Omnibus Incentive Plan. This represents a share issuance and capital structure change rather than an earnings announcement, AGM materials, or a regulatory filing. Therefore, it best fits the “Share Issue/Capital Change” category (SHA).
2025-08-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.